The findings in this study validate our company mission: to provide technology for early intervention of treatable conditions which help to improve patients’ quality of life.
Pine Brook, NJ (PRWEB) July 01, 2014
In a controlled clinical study, a team of researchers from New York Eye and Ear Infirmary concluded that test data from the Diopsys® NOVA-ERG vision test provides a way to discriminate both dry and wet Age-Related Macular Degeneration (AMD) eyes from healthy eyes. The study results published in a poster titled 'Steady State Pattern Electroretinography (ssPERG) in Age-Related Macular Degeneration (AMD) Compared to Controls’ was presented this year at the Association for Research in Vision and Ophthalmology (ARVO).
The innovative study compared patients with dry and wet AMD to normal controls. Patients with both dry and wet AMD showed significant decrease in field of vision ratio as compared to the control eyes. The results of this study show exciting promise in the ability to detect AMD in patients early so treatment may commence before the patient reaches advanced stages of the disease.
AMD is a common eye condition and a leading cause of vision loss among people 50 years of age and older. As AMD progresses, a blurred area near the center of vision is the most common symptom. Over time, the blurred area may grow larger or patients may develop blank spots in their central vision. AMD by itself does not lead to complete blindness, however, the loss of central vision in AMD can interfere with simple daily activities, such as the ability to see faces, drive, read, write, and cook.
“The findings in this study validate our company mission: to provide technology for early intervention of treatable conditions which help to improve patients’ quality of life,” said Joseph Fontanetta, President and CEO of Diopsys, Inc.
Diopsys, Inc. (http://www.diopsys.com) is the leading provider of patented, non-invasive electrophysiology instrumentation used to analyze visual pathways to detect and monitor visual and neuro-visual disorders. The company is dedicated to delivering high-quality, patient friendly, cost-effective preventative health care solutions.
Diopsys has developed and markets the Diopsys® NOVA-VEP and Diopsys® NOVA-ERG Vision Testing Systems utilized by optometrists and ophthalmologists to help in the detection, diagnosis and treatment of vision disorders, including Glaucoma, Age Related Macular Degeneration (AMD), and Multiple Sclerosis (MS). Diopsys also provides the Enfant® Pediatric VEP Vision Testing System, a device used in testing for visual deficits, including Amblyopia, in children as young as six months of age.